ONL Therapeutics’ $46.9 Million Series B Financing

January 11, 2021

This is an article about portfolio company, ONL Therapeutics, Inc.

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced it closed on $46.9 million in a Series B preferred stock financing.

View source version on globallegalchronicle.com: http://www.globallegalchronicle.com/onl-therapeutics-46-9-million-series-b-financing/